Form 4: ClearPoint Neuro Director B. Kristine Johnson Acquires 21,093 Restricted Stock Units

Director B. Kristine Johnson acquired 21,093 restricted stock units of ClearPoint Neuro, Inc. on May 16, 2024.

Summary

• On May 16, 2024, B. Kristine Johnson, a director of ClearPoint Neuro, Inc. (CLPT), acquired 21,093 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of CLPT common stock.
• The RSUs vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders.
• Following the transaction, Johnson directly owns 21,093 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs by a director generally reflects confidence in the company's prospects, but it's a routine transaction.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon continued service or the occurrence of the 2025 annual meeting.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of restricted stock units, which is a common form of equity compensation.

Stakeholder Impact

• The acquisition of restricted stock units by a director can be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates